Guardant Health introduced Guardant360, the first and most validated comprehensive liquid biopsy, in 2014. It has since been used by more than 3,000 oncologists to identify somatic genomic alterations associated with targeted therapies in the tumor DNA of more than 30,000 patients with advanced cancer.
"Guardant Health's leadership in comprehensive liquid biopsies gives it a unique foundation for developing tools across the cancer-care continuum, including the very difficult challenge of creating an accurate, non-invasive early detection test," Clark said. "I expect Guardant's influx of cancer genomic data to drive profound advances in our collective understanding of cancer and cancer management. And I'm excited to help make sure these innovations bring as much benefit to cancer patients as possible."
About Guardant Health
Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. Using both molecular and digital tools, Guardant Health is addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms. Its first product, Guardant360, came to market in 2014, and is now the most validated and sensitive comprehensive liquid biopsy commercially available. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
Media Contact: email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ian-clark-joins-guardant-health-board-of-directors-300386944.html
SOURCE Guardant Health